Literature DB >> 3744378

Monoclonal antibody CO17-1A and leukapheresis in immunotherapy of pancreatic cancer.

M A Tempero, P M Pour, E Uchida, D Herlyn, Z Steplewski.   

Abstract

Eighteen patients with measurable or evaluable advanced (metastatic or unresectable) adenocarcinoma of the pancreas were treated with a single infusion of monoclonal antibody CO17-1A in autologous leukocytes. No toxicity was experienced with treatment. Three of seventeen patients evaluable for response demonstrated unusually stable disease and a decrease in serum CA 19-9 antigen in two patients who expressed this biomarker. Human anti-mouse antibody developed in 81% of these patients. Monoclonal antibody CO17-1A may have a cytostatic effect in a small fraction of patients. Future clinical trials will focus on enhancing this effect with other immune modulators.

Entities:  

Mesh：

Substances：

Year:  1986        PMID： 3744378

Source DB:  PubMed          Journal:  Hybridoma        ISSN： 0272-457X


  13 in total

1.  Expression of human tumor-associated antigens in pancreatic cancer induced in Syrian hamsters.

Authors:  Y Takiyama; H Egami; P M Pour
Journal:  Am J Pathol       Date:  1990-03       Impact factor: 4.307

2.  Idiotypic cascades in cancer patients treated with monoclonal antibody CO17-1A.

Authors:  M Wettendorff; D Iliopoulos; M Tempero; D Kay; E DeFreitas; H Koprowski; D Herlyn
Journal:  Proc Natl Acad Sci U S A       Date:  1989-05       Impact factor: 11.205

Review 3.  Pancreatic cancer: a review of emerging therapies.

Authors:  L Rosenberg
Journal:  Drugs       Date:  2000-05       Impact factor: 9.546

4.  Investigational Strategies for Detection and Intervention in Early-Stage Pancreatic Cancer. April 24-27, Annapolis, Maryland. Abstracts.

Authors: 
Journal:  Int J Pancreatol       Date:  1994 Oct-Dec

5.  Humoral and cellular responses of colorectal cancer patients treated with monoclonal antibodies and interferon gamma.

Authors:  H M Blottiere; J Y Douillard; H Koprowski; Z Steplewski
Journal:  Cancer Immunol Immunother       Date:  1990       Impact factor: 6.968

6.  Cytokine-mediated enhancement of epidermal growth factor receptor expression provides an immunological approach to the therapy of pancreatic cancer.

Authors:  W Schmiegel; J Schmielau; D Henne-Bruns; H Juhl; C Roeder; P Buggisch; A Onur; B Kremer; H Kalthoff; E V Jensen
Journal:  Proc Natl Acad Sci U S A       Date:  1997-11-11       Impact factor: 11.205

Review 7.  Adjuvant therapy of pancreatic cancer using monoclonal antibodies and immune response modifiers.

Authors:  H Friess; M Gassmann; M W Büchler
Journal:  Int J Pancreatol       Date:  1997-02

8.  Immunohistochemical monitoring of metastatic colorectal carcinoma in patients treated with monoclonal antibodies (MAb 17-1A).

Authors:  J Shetye; J E Frödin; B Christensson; C Grant; B Jacobsson; S Sundelius; M Sylvén; P Biberfeld; H Mellstedt
Journal:  Cancer Immunol Immunother       Date:  1988       Impact factor: 6.968

9.  Dose-related comparison of antibody-dependent cellular cytotoxicity with chimeric and native murine monoclonal antibody 17-1A. Improved cytolysis of pancreatic cancer cells with chimeric 17-1A.

Authors:  Y Haga; C L Sivinski; D Woo; M A Tempero
Journal:  Int J Pancreatol       Date:  1994-02

Review 10.  Edrecolomab (monoclonal antibody 17-1A).

Authors:  J C Adkins; C M Spencer
Journal:  Drugs       Date:  1998-10       Impact factor: 9.546
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.